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Abstract The cell membrane is protected against lipid peroxida- 
tion through endogenous antioxidants such as the lipid soluble 
a-tocopherol. The anesthetic agent propofol (2,6-diisopropylphe- 
nol) has a chemical structure which is similar to ot-tocopherol, 
since it also contains a phenolic OH-group. The transient protec- 
tion of GSH against lipid peroxidation in control liver micro- 
somes is not observed in microsomes deficient in a-tocopherol. 
Introducing propofol (2 and 5 tiM) restored the protective ffect 
of GSH. Similar to the control microsomes the GSH-protective 
effect did not occur in previously heated microsomes. These re- 
sults suggest that propofol acts similarly to a-tocopherol as a 
chain breaking antioxidant in liver microsomal membranes. 
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1. Introduction 
Tissue damage caused by the activity of reactive oxygen 
species (ROS) plays a role in many clinical situations uch as 
ARDS, sepsis, multiple organ failure and ischemia-reperfusion 
[1,2]. As a consequence of the activity of ROS, lipid peroxida- 
tion can occur. The polyunsaturated fatty acids in the cell 
membrane are protected against lipid peroxidation through 
endogenous antioxidants such as the lipid-soluble chain-break- 
ing antioxidant (a-tocopherol) [3,4]. ~-Tocopherol terminates 
the chain reaction of lipid peroxidation by scavenging lipidper- 
oxyl radicals (LOO') by a process of hydrogen donation. In this 
reaction ~-tocopherol itself becomes a radical which is, how- 
ever, much less reactive than LOO" (reaction 1) [3]: 
a-Tocopherol-OH + LOO" --* a-tocopherol-O" + LOOH (1) 
The hydroxyl (OH) group of the chroman moiety of a-toco- 
pherol donates the hydrogen atom. The anesthetic agent pro- 
pofol (2,6-diisopropopylphenol) also contains a phenolic OH- 
group (Fig. 1) and has been reported to be an antioxidant [5,6]. 
We hypothesized that propofol might act similarly to c~-toco- 
pherol as a chain-breaking antioxidant and could substitute for 
a-tocopherol. It has already been shown that propofol, used in 
clinically relevant concentrations, could inhibit lipid peroxida- 
tion in liver microsomes and mitochondria [5,6]. In order to 
keep the levels of a-tocopherol high enough to protect the 
membranes against lipid peroxidation, the antioxidant is con- 
tinuously recycled in the liver. In this process of recycling, via 
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a so-called free radical reductase in liver-microsomes, the 
cc-tocopherol radical, formed in reaction 1, is regenerated to
cc-tocopherol by the cytosolic thiol GSH [7]. This system is 
excellently suited to test our hypothesis that propofol can re- 
place a-tocopherol. 
2. Materials and methods 
2.1. Microsomes 
The microsomes were prepared from male Wistar ats, 200-250 g, as 
described before, and stored at -80°C [7]. Control microsomes were 
prepared by washing the stored microsomes twice by centrifugation [7]. 
a-Tocopherol was extracted from the microsomes according to Maior- 
ino et al. [10]. In short, the stored microsomes were thawed and mixed 
with 2 vols. of ice-cold acetone and shaken vigorously. After 5 min the 
microsomes were washed twice by centrifugation. Care was taken to 
remove all the acetone, since it was observed that acetone interfered 
with the method used to detect lipid peroxidation (acetone reacts with 
thiobarbituric acid). The pellet obtained after centrifugation of the 
c~-tocopherol-extracted microsomes was resuspended in 50 mM Tris- 
HC1 (pH 7.4, 37°C) containing 150 mM KCI. Propofol was added to 
the microsomes. After the addition of propofol, the microsomes were 
washed twice and harvested again by centrifugation. 
2.2. Incubation conditions 
Microsomes (final concentration derived from 1/8 g liver/ml) were 
incubated at 37°C, with shaking, and oxygen was freely admitted in 
Tris-HC1/KC1 (50 mM/150 mM, pH 7.4). Ascorbic acid and GSH were 
neutralized with KOH before addition. Reactions were started by add- 
ing a freshly prepared FeSO4 solution. 
OH 
(CH3)2HC~CH(CH3)2  
2,6-diisopropylphenol 
(propofol) 
CH3 
HO~[(CH2)3CHCH3]3CH3 
O / ~H3 
H3C 
CH3 
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Fig. 1. Chemical structure of propofol and c~-tocopherol. 
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2.3. LipM peroxidation assay 
Lipid peroxidation was assayed by measuring thiobarbituric acid 
(TBA)-reactive material. The reaction in an aliquot of the incubation 
mixture (0.3 ml) was stopped by mixing with ice-cold TBA-TCA-HC1- 
BHT solution (2 ml; see below). After heating (15 rain, 80°C) and 
centrifugation (15 min) the absorbance at 535 nm vs. 600 nm was 
determined. For the TBA-TCA-HCl-butyl-hydroxytoluene (BHT) so- 
lution, a TBA-TCA solution was prepared by dissolving 41.6 mg TBA/ 
10 ml trichloroacetic a id (16.8% w/v in 0.25 N HCI). To 10 ml TBA- 
TCA-HC1 1 ml BHT (1.5 mg/ml ethanol) was added. The added chem- 
icals did not interfere with the assay at the concentrations u ed. The 
data are the mean + S.D. from 5 duplicate xperiments. 
2.4. Measurement of cz-tocopherol 
To measure ~-tocopherol, it was extracted from the membrane by 
heptane according to the method of Burton et al. [11]. cz-Tocopherol 
was quantified using HPLC (C18 nucleosil column; Chrompack, The 
Netherlands; eluted with 98% methanol, flow rate 0.6 ml/min) with 
fluorometric detection (excitation 295 nm, emission 340 nm). 
3. Results 
GSH (1 mM) gives a transient protection against lipid perox- 
idation in control iver microsomes (Fig. 2). Heating (100°C) 
these microsomes for 60 s abolished this GSH-protection (data 
not shown). After extraction with acetone the ~z-tocopherol 
concentration i the microsomes dropped from 0.68 + 0.08 
nmol/mg protein to a concentration which could not be de- 
tected anymore. In these ct-tocopherol-deficient microsomes, 
GSH (1 mM) could not protect against lipid peroxidation any- 
more (Fig. 3). By introducing propofol (2 or 5 #M) into the 
~z-tocopherol-deficient membranes the transient protective f- 
fect of GSH (1 mM) could be restored (which was dependent 
on the concentration fpropofol used; Fig. 3). Both 2 and 5 #M 
propofol did not protect the cz-tocopherol-deficient microsomes 
directly (data not shown). When the propofol was introduced 
in microsomes, which were heated (100°C) before propofol was 
introduced, propofol was not able to restore the protection by 
GSH (data not shown). Moreover, the latter data indicate that 
propofol itself, in the concentrations used, did not protect again 
Fe2+/ascorbate-induced liv r microsomal lipid peroxidation. 
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Fig. 2. Time-course of lipid peroxidation i duced by 10 #M Fe 2+ and 
0.2 mM ascorbate incontrol microsomes (©) or in the presence of1 mM 
GSH (e). The insert shows the interaction of cc-tocopherol and GSH 
in the protection against lipid peroxidation. The cz-tocopherol adicals 
are regenerated to ~z-tocopherol by GSH. This reaction is catalyzed by 
the heat-labile free radical reductase [7]. 
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Fig. 3. Time-course of lipid peroxidation i duced by 10 #M Fe 2+ and 
0.2 mM ascorbate in c~-tocopherol-deficient microsomes without (A) 
and with (a) the addition of GSH (1 mM). The microsomes towhich 
GSH (1 mM) was added were nriched with 2#M propofol (o) or 5 #M 
propofol (e). 
4. Discussion 
The protective ffect of GSH against Fe2÷/ascorbate-induced 
lipid peroxidation i liver microsomes depends on the presence 
of cz-tocopherol. In liver microsomes from animals fed a cz- 
tocopherol-deficient diet, as well as in microsomes from which 
~z-tocopherol was extracted with acetone, GSH did not protect 
against lipid peroxidation [8,9]. In the latter experiment the 
GSH-dependent protection could be restored by adding ~-toco- 
pherol to the cz-tocopherol-depleted microsomes [10]. The anes- 
thetic agent propofol (2,6 diisopropylphenol) chemically resem- 
bles the chain-breaking antioxidant cz-tocopherol, because it 
also has a phenolic hydroxyl group [12]. This phenolic hydroxyl 
group is responsible for the antioxidant properties of propofol, 
as found in various in vitro experiments [5,6,12]. We show that 
introducing propofol in to cz-tocopherol-depleted microsomes 
restores the GSH-dependent protection. When propofol is in- 
troduced in to ~-tocopherol-depleted microsomes, which were 
heated (100°C) beforehand, the GSH-dependent protection is
completely ost. This is similar to what is found in normal iver 
microsomes, i.e. the GSH-dependent protection is heat labile. 
This suggests that propofol can take over the role of ~z-tocophe- 
rol. The heat-labile free radical reductase, catalyses this recy- 
cling reaction (Fig. 4). Our data also suggest hat the free 
radical reductase is not specific for ct-tocopherol, but also acts 
with ~-tocopherol look-alike compounds like propofol. Pro- 
pofol, because of its good lipid solubility, is able to penetrate 
into membranes. The concentrations ofpropofol which are able 
to inhibit he lipid peroxidation and to replace the cz-tocopherol 
function in cell membranes are in the range which is clinically 
used in anesthesia. Peak plasma concentrations of propofol of 
40-60/,tmol/l occur with the induction of anesthesia, nd during 
the maintenance of anesthesia the anesthetic concentrations are 
1 0-25 #mol/1 [13]. Therefore the antioxidant properties of pro- 
pofol can be of clinical importance. In many clinical situations 
where oxidative stress plays a role, the cz-tocopherol content of 
the cellular membranes will be decreased, making these mem- 
branes even more vulnerable tooxidative stress [14-17]. Restor- 
ing the ct-tocopherol concentration i  acute situations i very 
difficult. So, during anesthesia for cardiac or vascular surgery, 
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Fig. 4. Propofol probably acts as a chain-breaking antioxidant inwhich 
the propofol radical is formed. The subsequent reduction of the pro- 
pofol radical by the liver microsomal GSH-dependent free radical re- 
ductase regenerates propofol in a similar way as it regenerates a-toco- 
pherol. 
for transplantation surgery or during sedation of the critically 
ill, artificially ventilated patients in the Intesive Care Unit 
( ICU) with sepsis, severe burns, etc., propofol could be an 
effective inhibitor of lipid peroxidation. It might support or 
even take over this anti-oxidant function of ~-tocopherol. The 
clinical consequences of inhibition of membrane lipid peroxida- 
tion in these situations have never been studied in patients. 
Propofol being an already widely accepted rug in anesthesia 
as well as for sedation in the ICU, would be an interesting 
compound to further study the clinical consequences of phar- 
macological intervention of oxidative stress. 
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